Skip to main content
. 2022 Jun 10;10(6):e004322. doi: 10.1136/jitc-2021-004322

Figure 2.

Figure 2

DuoBody-CD40×4-1BB exhibits conditional agonist activity. (A) CD40 bioluminescent cell-based reporter assay in the absence or presence of 4-1BB-expressing K562 cells. Cells were incubated with DuoBody-CD40×4-1BB, recombinant CD40L or control antibodies. (B) Human peripheral blood B cells were cocultured with 4-1BB-transgenic or wild type K562 cells in the presence of DuoBody-CD40×4-1BB for 48 hours. Expression of CD69 and CD86 on CD20+ B cells was analyzed by flow cytometry. Data shown are mean percentages of CD69+ or CD86+ B cells from one representative donor (n=3). Error bars represent SD. (C) 4-1BB bioluminescent cell-based reporter assay in the absence or presence of CD40-expressing K562 cells. Fold luminescence-induction of cells incubated with DuoBody-CD40×4-1BB or control antibodies, compared with treatment control (isotype control antibody or media only) is shown. Error bars represent SD. RLU, relative luminescence units.